-
EHA Expert Interview | Three Studies from Professor Sanbin Wang’s Team Selected for EHA: An In-Depth Review
The 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars worldwide to share and discuss innovative ideas and the latest scientific and clinical research achievements in hematology. At this…
-
BOC/BOA 2024丨Professor Xiaojie Bian: Radioligand Therapy & PROTAC Treatment Bring New Hope for mCRPC
From July 5 to 7, 2024, the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA) was grandly held in Guangzhou. On the 6th, Professor Xiaojie Bian from Fudan University Shanghai Cancer Center shared the latest drug development progress for metastatic castration-resistant prostate cancer (mCRPC) from the 2024…
-
Embrace the synergy of global expertise and local insights with Professor Zefei Jiang at the 2024 Best of ASCO/Best of CSCO.
As the Vice Chairman and Secretary-General of the Chinese Society of Clinical Oncology (CSCO), he leads the charge in aligning Chinese clinical oncology with international standards. Experience the cutting-edge advancements in targeted therapies, immunotherapies, and the integration of precision medicine. Let’s innovate together for a future where cancer treatment knows no borders.
-
Pre-ACLF and Other Different Clinical Courses of Acute Decompensated Cirrhosis
ACLF Monthly Review” is a special academic review column on ACLF invited by the editorial department of Hepatology Digest, created by the Chinese Acute-on-Chronic Liver Failure Consortium (Ch-CLIF-C). Each month, this column focuses on a specific area related to ACLF, aiming to popularize the concept and significance of ACLF and help readers quickly understand developments…
-
BOC/BOA Innovation Forum | Professor Jun Guo and ProfessorPei Dong: An Overview of Advances in Kidney Cancer Treatment and the Pulse of Combination Therapy
From July 5-7, 2024, the 2024 Chinese Clinical Oncology Annual Progress Seminar (BOC) and Beast of ASCO® 2024 China were grandly held in Guangzhou. On the 6th, a special session on urinary system tumors convened, gathering significant progress from ASCO. In the field of kidney cancer treatment, besides international advancements, China has made significant strides…
-
Professor Songqing Ye: Heterogeneity in HER2 Expression in Breast Cancer and Novel ADC Treatment Strategies
In recent years, the accurate detection of HER2 (human epidermal growth factor receptor 2) expression in breast cancer has become crucial for guiding personalized treatment strategies. However, the heterogeneity of HER2 expression, including spatial and temporal heterogeneity, poses challenges for clinical decision-making. In this article, Professor Songqing Ye from Fujian Provincial Hospital delves into the…
-
ASCO 2024 Researcher Insights丨Professor Yeon Hee Park Discusses Updated Survival Results from the Randomized Phase II Young-PEARL Study
For premenopausal patients with HR+/HER2- metastatic breast cancer (mBC), treatment choices are complex due to physiological characteristics, tumor properties, and treatment tolerance. Many patients receive chemotherapy early due to endocrine resistance and concerns about rapid tumor progression, with capecitabine being a commonly used regimen. At the 2024 ASCO conference, the latest updated survival results from…
-
ASCO Hot Review丨Professor Qiang Zhang: Multi-Gene Testing Facilitates Precision Treatment for HR+/HER2- Early-Stage Breast Cancer Patients
In the field of breast cancer treatment, gene testing for early-stage breast cancer has become a vital component of precision medicine. By deeply analyzing the genetic expression profiles of patients, we can more accurately predict disease progression and develop more personalized adjuvant treatment strategies. However, how is gene testing currently applied in clinical practice, and…
Connecting Medical Expertise through Media